Brought to you by 
DARA BioSciences out-licenses DB959 to T3D Therapeutics
01 Aug 2022
Executive Summary
As part of its strategy to focus on selling oncology supportive care products, DARA BioSciences Inc. has licensed T3D Therapeutics Inc. (CNS therapies) exclusive worldwide rights to develop and commercialize DB959.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DARA BioSciences out-licenses DB959 to T3D Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice